N-[3-(dimethylamino)propyl]-3-methoxybenzamide | 331989-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-(dimethylamino)propyl]-3-methoxybenzamide
• CAS: 331989-45-8
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: KLPYTQCAMGXQKM-UHFFFAOYSA-N

物化性质

• 沸点：
  375.8±27.0 °C(Predicted)
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  间甲氧基苯甲酰氯 、 N,N-二甲基-1,3-二氨基丙烷 以 二氯甲烷 为溶剂， 以51%的产率得到N-[3-(dimethylamino)propyl]-3-methoxybenzamide
  参考文献：
  名称：

  Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the Acanthocheilonema viteae Product ES-62 Prevents Development of Collagen-Induced Arthritis

  摘要：

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,

  DOI：

  10.1021/jm401251p

文献信息

• [EN] 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] COMPOSÉS CHIMIQUES 1-994
  申请人：ASTRAZENECA AB

  公开号：WO2009024824A1

  公开（公告）日：2009-02-26

  The invention relates to chemical compounds of the formula (I), or a pharmaceutically acceptable salt thereof, which possess inhibitory activity against the spindle checkpoint kinase: Tyrosine Threonine Kinase (TTK)/monopolar spindle 1 (Mpsl) and are accordingly useful for their anti-cancer effect in a warm-blooded animal such as man. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of a medicament for the treatment of conditions mediated by TTK/Mpsl, for use either alone or in combination with other anti-pro liferative agents.

  该发明涉及化合物的化学式（I）或其药学上可接受的盐，这些化合物具有对纺锤体检查点激酶：酪氨酸苏氨酸激酶（TTK）/单极纺锤体1（Mpsl）的抑制活性，因此在诸如人类之类的恒温动物中对其抗癌效果有用。该发明还涉及制造所述化合物的过程，含有它们的药物组合物，以及它们在制造用于治疗由TTK/Mpsl介导的疾病的药物时的使用，可以单独使用或与其他抗增殖剂组合使用。
• 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：AstraZeneca AB

  公开号：EP2212326A1

  公开（公告）日：2010-08-04
• Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the <i>Acanthocheilonema viteae</i> Product ES-62 Prevents Development of Collagen-Induced Arthritis
  作者：Lamyaa Al-Riyami、Miguel A. Pineda、Justyna Rzepecka、Judith K. Huggan、Abedawn I. Khalaf、Colin J. Suckling、Fraser J. Scott、David T. Rodgers、Margaret M. Harnett、William Harnett

  DOI：10.1021/jm401251p

  日期：2013.12.27

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,